WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Firm News

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million. 

Stuart Falber led the WilmerHale team representing Tetraphase in this transaction, with a team that included Chris Barnstable-Brown, Emily Gainor and Tim Kulis

Visit www.tetraphase.com for more information. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.